Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Helius Medical Technologies reports Q1 revenue, eyes CMS reimbursement boost

Helius Medical Technologies navigated Q1 2024 with a focus on reimbursement, FDA approval, and financial sustainability, supported by financing and market expansion initiatives.
Progress in securing reimbursement, expanding market reach, and addressing demand signals growth potential and market acceptance for the company's products.
Challenges in achieving profitability and executing development plans underscore the importance of timely reimbursement and effective operational strategies.

Helius Medical Technologies navigates revenue challenges with strategic growth initiatives

Helius Medical Technologies faces challenges from program terminations impacting revenue and ongoing operating losses, but maintains a strong cash position with no debt.
Efforts to expand access to PoNS Therapy through strategic partnerships and sales initiatives present growth opportunities in the MS and stroke treatment markets.
The company's financial performance in Q2 2024 reflects a mixed picture of revenue decline, operational losses, and cash stability, with potential for growth pending reimbursement determinations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Dane Andreeff - President & Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jonathan Aschoff - ROTH Capital Partners Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Q3 2022 Earnings Call.

Helius Medical Technologies, Inc. (HSDT) Q3 2022 Earnings Call Transcript

-- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am today -- NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022.

Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

-- Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the participation of Prue Plummer PhD, PT, Professor in the Department of Physical Therapy in the School of Health and Rehabilitation Sciences at the MGH Institute of Health Professions to its Therapeutic Experience Program (“TEP”). The MGH Institute of Health Professionals joins NYU Langone Health, the Shepherd Center, and Oregon Health & Science University as the fourth Center of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects' adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (“MS”).

Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

-- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- -- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis --

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training

Helius to Showcase Innovative PoNS Device at ACRM's 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

NEWTOWN, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the market opens.

Helius Medical Technologies, Inc. to Release Third Quarter 2022 Financial Results on November 14, 2022

Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy Month Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy Month

Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait

NEWTOWN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference, as follows:

Helius Medical Technologies to Present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference

Avenue Therapeutics

Bird Rides

VistaGen Therapeutics

Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $0.99 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Buy For Under $0.99 This Week

NEWTOWN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming healthcare conferences as follows:

Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September

CASI Pharmaceuticals

HCW Biologics

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

New Concept Energy

Lufax Holding

Ring Energy

Vivakor

There seems to be a disconnect between the broader markets and penny

5 Penny Stocks To Buy For Under $5 Right Now

A curious $14.5m microcap that $100m in value has transacted through in just 15 trading sessions. A recent equity raise increased cash position by $16.4m in August. The company is currently net-net trading below net current asset value. P/B is 0.69x.

Helius Medical Technologies: A Net-Net Meme Stock In The Making

What Makes Helius Medical Technologies, Inc. (HSDT) a New Buy Stock

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Lisa Wilson - Investor Relations Dane Andreeff - President & Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Good day and thank you for standing by. Welcome to the Helius Medical Technologies' Q2 2022 Earnings Conference Call.

Helius Medical Technologies, Inc. (HSDT) CEO Dane Andreeff on Q2 2022 Results - Earnings Call Transcript

-- Net proceeds from August 2022 financing and cash on hand expected to fund operations through 2023 -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.

Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results

NEWTOWN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its second quarter 2022 financial results on Monday, August 15, 2022, after the market closes.

Helius Medical Technologies, Inc. to Release Second Quarter 2022 Financial Results on August 15, 2022

NEWTOWN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and (ii) warrants to purchase up to 36,000,000 shares of its Class A common stock (“Public Warrants”) at a purchase price of $0.75 per share and associated Public Warrant. The Public Warrants will have an exercise price of $0.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about August 9, 2022, subject to customary closing conditions.

Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering

Eos Energy Enterprises

Mizuho Financial Group

Check these penny stocks out for your watchlist right now The post Big Gaining Penny Stocks to Buy? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Big Gaining Penny Stocks to Buy? 3 to Watch Today

-- Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand -- -- Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand --

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™

Helius Medical Technologies, Inc. (HSDT) Upgraded to Buy: Here's Why

-- Study finds significant improvement in gait deficit in multiple sclerosis patients using translingual neurostimulation (“PoNS Therapy®”) combined with a therapeutic exercise program -- -- Poster was one of ten rehabilitation research presentations nominated for the Labe C. Scheinberg Award recognizing the platform or poster, in each therapeutic category, that has the greatest impact in advancing the care of people with MS --

Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting

New program seeks to expand access to patients suffering from multiple sclerosis (MS) New program seeks to expand access to patients suffering from multiple sclerosis (MS)

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting taking place June 1-4 in National Harbor, Maryland.

News for Helius Medical Technologies Stock (HSDT)